Denmark’s pharmaceutical heavyweight, Novo Nordisk (NYSE: NVO), has reached a significant milestone with the National Medical Products Administration (NMPA) accepting its market filing for Sogroya (somapacitan), a long-acting somatotropin. This once-weekly treatment is designed to address adult growth hormone deficiency (AGHD) and has already received approval in the US in August 2020. A pivotal Phase III clinical study has demonstrated that Sogroya is equivalent to the once-daily short-acting somatotropin in delivering clinical benefits, marking a potential shift in the treatment paradigm for patients with AGHD. – Flcube.com
Recent news:
-
Shanghai Designates Backup Suppliers and Specialized Drug Formulations in GY-YD2024-2 Procurement -
Abbott Laboratories' Volt PFA System Receives EU CE Mark for Atrial Fibrillation Treatment -
Alcon Laboratories Acquires Majority Stake in Aurion Biotech to Advance Eye Disease Cell Therapy -
Genmab's Tivdak Approved in Japan for Advanced Cervical Cancer Treatment -
CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline
